Journavx vs. Opioids: Why Acute Pain Treatment Is Changing in 2025

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | December 24, 2024 | 8 min read

Journavx (suzetrigine) is the first non-opioid, non-NSAID analgesic in over 20 years with FDA approval for moderate-to-severe acute pain. For personal injury patients who need real pain relief without the risks of opioids, Journavx represents a genuine clinical breakthrough. Here's how it compares.

Journavx vs. Opioids: Why Acute Pain Treatment Is Changing in 2025

For decades, the management of moderate-to-severe acute pain in personal injury patients has rested on two pillars: NSAIDs for milder pain, and opioids for anything more severe. In February 2025, that calculus changed. The FDA approved Journavx (suzetrigine) — the first in a new class of non-opioid analgesics targeting a specific pain channel in the peripheral nervous system — for moderate-to-severe acute pain.

Journavx doesn't just represent an alternative to opioids. It represents a fundamentally different approach to pain management that eliminates the core risks that make opioids problematic in personal injury cases.

[!KEY] Journavx blocks pain signals at the peripheral nerve before they reach the brain — providing meaningful relief for moderate-to-severe acute pain without sedation, addiction risk, or controlled substance documentation.

[!SOURCE] Suzetrigine (Journavx) — FDA Approval — First-in-class Nav1.8 inhibitor; FDA approved January 2025 for acute pain.

What Makes Journavx Different

The key to understanding Journavx is understanding where it acts. Opioids work primarily in the brain and spinal cord — the central nervous system. They relieve pain by blunting the brain's perception of pain signals, but this central mechanism is also what creates addiction, sedation, respiratory depression, and impaired cognition.

Journavx targets Nav1.8 — a sodium channel found almost exclusively in peripheral sensory neurons (the pain-sensing nerves in the body, not the brain or spinal cord). By blocking this channel selectively in peripheral nociceptors, Journavx interrupts pain signals before they reach the brain, without affecting the brain itself.

The result: effective, clinically meaningful pain relief for moderate-to-severe acute pain, with none of the central nervous system effects of opioids.

Head-to-Head: What Each Drug Does in the Body

The Personal Injury Case for Journavx

Injury Severity Without the Controlled Substance Burden

An opioid prescription in a PI case is a double-edged sword. It documents significant pain — which supports damages — but it also creates controlled substance documentation that opposing counsel can attempt to exploit. Defense attorneys may argue that the patient "needed narcotics" in a way intended to raise questions about pre-existing addiction or drug-seeking behavior.

Journavx solves this problem. A Journavx prescription documents:

• Pain severity significant enough that the prescribing physician reached for a non-NSAID prescription analgesic
• A physician who selected a state-of-the-art, non-addictive pain medication
• Acute pain management without any controlled substance, abuse potential, or dependency risk

The same injury severity is documented — moderate-to-severe acute pain requiring prescription-class analgesia — without the controlled substance record.

Functional Preservation

Opioids impair driving, cognitive function, and work performance. PI patients on opioids cannot drive, often cannot work, and may be cognitively compromised during attorney meetings, depositions, and medical appointments.

Journavx does not impair any of these functions. A patient taking Journavx for acute post-accident pain can:

• Drive to medical appointments and PT
• Maintain employment during recovery
• Participate fully in their legal case
• Perform physical therapy with cognitive engagement

The drug works peripherally — the brain is unaffected.

[!KEY] A patient taking Journavx for severe acute pain presents better at depositions and IMEs than a patient on opioids — cognitively clear and functional, which strengthens credibility without sacrificing the injury severity documentation the prescription itself provides.

[!KEY] Journavx prescribing in 2025 signals that the treating physician is practicing at the leading edge of pain medicine — which is itself a narrative point: this patient received state-of-the-art care because their injury warranted it.

New Standard of Care Argument

For PI cases involving ongoing medical treatment, Journavx also creates a compelling narrative: this patient is receiving the most advanced, evidence-based non-opioid pain management available. Their treating physician is using 2025-era medicine, not defaulting to 30-year-old opioid protocols. This framing supports the legitimacy and appropriateness of the overall treatment plan.

What Journavx Does NOT Replace

Journavx is FDA-approved for acute pain only (currently). It is not approved for:

• Neuropathic pain (nerve damage) — gabapentinoids and SNRIs continue to be the appropriate agents
• Chronic pain — Journavx is not indicated for ongoing chronic pain management
• Inflammatory pain as a primary target — NSAIDs remain first-line for inflammatory pain

For PI patients with both acute injury pain and nerve involvement, the clinical approach typically combines Journavx for acute nociceptive pain with a gabapentinoid for neuropathic components. The two mechanisms are complementary.

Why Some Physicians Still Choose Opioids

Despite Journavx's advantages, opioids remain clinically appropriate in specific situations:

• Severe post-surgical pain: For post-operative pain following orthopedic surgery, opioids remain a standard component of acute post-op protocols. Journavx may complement but not fully replace opioids in this setting yet.
• When non-opioid analgesics are insufficient: If a patient does not achieve adequate pain control with Journavx plus NSAIDs plus other modalities, opioids may still be necessary.
• Established opioid protocols: Some practices have established, well-monitored opioid protocols that have worked well for specific patient populations.

The key question for PI cases is not "opioids are always wrong" but rather: given the availability of Journavx, has the prescriber considered it, and what is the clinical rationale for the chosen approach?

The Historical Context: Why This Approval Matters

The last truly novel class of non-opioid prescription analgesic approved by the FDA before Journavx was tramadol in 1995 — and tramadol itself became a controlled substance after widespread misuse. Before Journavx, if a physician needed to treat moderate-to-severe acute pain with something stronger than an NSAID, opioids were essentially the only option.

The Nav1.8-selective mechanism is the result of decades of research identifying why some people feel pain more intensely than others. Nav1.8 channels are overexpressed in injury states — the same channels that amplify pain signals after trauma are the specific target of suzetrigine. This targeted approach is what makes the drug effective without requiring the broad CNS suppression of opioids.

What's Next: The Nav1.8 Pipeline

Suzetrigine's approval opens the door to a new class of pain medications. Multiple pharmaceutical companies are now developing second-generation Nav1.8 inhibitors and related ion channel modulators. Personal injury pharmacy will look increasingly different over the next 5-10 years as this mechanism class matures.

LienScripts provides pharmacy lien coverage for Journavx at $0 upfront cost for qualified personal injury patients. Contact LienScripts to discuss coverage for your clients.

Related Resources

• Journavx (Suzetrigine): The First Nav1.8 Pain Blocker
• Non-Opioid Pain Management in Personal Injury Cases: 2025 Update
• Why PI Patients Often Need Multiple Medications
• Pharmacy Services for Personal Injury Clients: How It Works
• Gabapentin for Personal Injury Cases: What Attorneys Need to Know
• What Are Medication Liens?